AstraZeneca to Evaluate Compendia's Oncomine Software | GenomeWeb
NEW YORK (GenomeWeb News) - AstraZeneca has licensed Compendia Bioscience’s data mining and visualization software, Compendia said today.
 
AstraZeneca will use the company’s Oncomine Concepts Edition software in a year-long pilot program in order to evaluate how it can be used in its cancer research programs.
 
Oncomine combines almost 7,000 proprietary cancer gene signatures with 11,000 gene, drug, and pathway signatures taken from the literature and other public sources, Compendia said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.